All In Biotech

Drug Trial Radar · NCT06277765

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Mar 21, 2024

Primary completion

Jan 23, 2025

Study completion Jan 23, 2025

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • CM310Biological

    Interleukin-4 receptor(IL-4Rα) monoclonal antibody

  • placeboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving EASI-75 at week 18Time frame: Up to week 18
  2. Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baselineTime frame: up to week 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.